Cogent Biosciences is targeting systemic mastocytosis, a rare disorder that causes the body to produce too many abnormal mast cells. These cells are part of the immune system, but when they build up and activate abnormally they can cause symptoms similar to allergic reactions. Severe reactions can include anaphylaxis, inflammation and organ damage.
Cogent is active in a rare disease where patients can be hard to diagnose, symptoms can be serious and testing is central to identifying the right population. In biotechnology, commercial opportunity often depends on whether patients can be found, diagnosed and treated through a clear clinical pathway.
Cogent describes two main types: advanced systemic mastocytosis and non-advanced systemic mastocytosis. Advanced disease is life-threatening and may shorten life expectancy because mast cells infiltrate major organs. Symptoms may include fatigue, nausea, malabsorption, weight loss, low blood counts, bone pain or fractures, abnormal liver function and enlargement of the liver or spleen.
Non-advanced systemic mastocytosis is described as a lifelong disease that can still have a major effect on quality of life. Symptoms may include itching, skin lesions, flushing, wheezing, shortness of breath, fatigue, allergic reactions, abdominal pain, diarrhoea, nausea, vomiting, brain fog, dizziness, memory issues, mood changes, trouble concentrating and bone pain.
Biotech Growth Trust lists Cogent Biosciences as one of its ten largest holdings as at 30 April 2026, representing 2.8% of total investments.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.
